Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2008 1
2009 2
2010 1
2011 1
2013 4
2014 6
2015 15
2016 22
2017 17
2018 30
2019 31
2020 40
2021 48
2022 64
2023 48
2024 48
2025 69
2026 22

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

428 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean attfield (427 results)?
Recent advances in Tumor Treating Fields (TTFields) therapy for glioblastoma.
Khagi S, Kotecha R, Gatson NTN, Jeyapalan S, Abdullah HI, Avgeropoulos NG, Batzianouli ET, Giladi M, Lustgarten L, Goldlust SA. Khagi S, et al. Oncologist. 2025 Feb 6;30(2):oyae227. doi: 10.1093/oncolo/oyae227. Oncologist. 2025. PMID: 39401002 Free PMC article. Review.
We describe new data showing that TTFields therapy has efficacy in a broad range of patients, with a tolerable safety profile extending to high-risk subpopulations. New analyses of clinical study data also confirmed that overall and progression-free survival positively cor …
We describe new data showing that TTFields therapy has efficacy in a broad range of patients, with a tolerable safety profile extendi …
Association of Tumor Treating Fields (TTFields) therapy with survival in newly diagnosed glioblastoma: a systematic review and meta-analysis.
Ballo MT, Conlon P, Lavy-Shahaf G, Kinzel A, Vymazal J, Rulseh AM. Ballo MT, et al. J Neurooncol. 2023 Aug;164(1):1-9. doi: 10.1007/s11060-023-04348-w. Epub 2023 Jul 26. J Neurooncol. 2023. PMID: 37493865 Free PMC article.

Meta-analysis of comparative studies indicated a significant improvement in OS for patients receiving TTFields and SOC versus SOC alone (HR: 0.63; 95% CI 0.53-0.75; p < 0.001). Among real-world post-approval studies, the pooled median OS was 22.6 months (95% CI 17.6-41.

…
Meta-analysis of comparative studies indicated a significant improvement in OS for patients receiving TTFields and SOC versus SOC alo …
Theory and application of TTFields in newly diagnosed glioblastoma.
Yu A, Zeng J, Yu J, Cao S, Li A. Yu A, et al. CNS Neurosci Ther. 2024 Mar;30(3):e14563. doi: 10.1111/cns.14563. CNS Neurosci Ther. 2024. PMID: 38481068 Free PMC article. Review.
However, TTFields still has the potential to further prolong the survival of ndGBM patients. AIM: By summarizing the mechanism and application status of TTFields in the treatment of ndGBM, the application prospect of TTFields in ndbm treatment is prospected. …
However, TTFields still has the potential to further prolong the survival of ndGBM patients. AIM: By summarizing the mechanism and ap …
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial.
Stupp R, Taillibert S, Kanner A, Read W, Steinberg D, Lhermitte B, Toms S, Idbaih A, Ahluwalia MS, Fink K, Di Meco F, Lieberman F, Zhu JJ, Stragliotto G, Tran D, Brem S, Hottinger A, Kirson ED, Lavy-Shahaf G, Weinberg U, Kim CY, Paek SH, Nicholas G, Bruna J, Hirte H, Weller M, Palti Y, Hegi ME, Ram Z. Stupp R, et al. JAMA. 2017 Dec 19;318(23):2306-2316. doi: 10.1001/jama.2017.18718. JAMA. 2017. PMID: 29260225 Free PMC article. Clinical Trial.
INTERVENTIONS: Patients were randomized 2:1 to TTFields plus maintenance temozolomide chemotherapy (n = 466) or temozolomide alone (n = 229). ...Systemic adverse event frequency was 48% in the TTFields-temozolomide group and 44% in the temozolomide-alone group. Mild …
INTERVENTIONS: Patients were randomized 2:1 to TTFields plus maintenance temozolomide chemotherapy (n = 466) or temozolomide alone (n …
Tumor Treating Fields (TTFields) Therapy Concomitant with Taxanes for Cancer Treatment.
Vergote I, Macarulla T, Hirsch FR, Hagemann C, Miller DS. Vergote I, et al. Cancers (Basel). 2023 Jan 19;15(3):636. doi: 10.3390/cancers15030636. Cancers (Basel). 2023. PMID: 36765594 Free PMC article. Review.
TTFields selectively target cancer cells through a multi-mechanistic approach without affecting healthy cells and tissues. ...In this review, we explore TTFields therapy concomitant with taxanes in both preclinical and clinical settings. The summarized data suggest …
TTFields selectively target cancer cells through a multi-mechanistic approach without affecting healthy cells and tissues. ...In this …
Efficacy and safety of adjuvant TTFields plus pembrolizumab and temozolomide in newly diagnosed glioblastoma: A phase 2 study.
Chen D, Le SB, Ghiaseddin AP, Manektalia H, Li M, O'Dell A, Rahman M, Tran DD. Chen D, et al. Med. 2025 Sep 12;6(9):100708. doi: 10.1016/j.medj.2025.100708. Epub 2025 Jun 4. Med. 2025. PMID: 40466642 Free article. Clinical Trial.
METHODS: In this phase 2 study (this study was registered at ClinicalTrials.gov: NCT03405792), 31 newly diagnosed glioblastoma patients were enrolled post-chemoradiation to evaluate synergy between TTFields, pembrolizumab, and temozolomide. The primary endpoint was progres …
METHODS: In this phase 2 study (this study was registered at ClinicalTrials.gov: NCT03405792), 31 newly diagnosed glioblastoma patients were …
A review of tumor treating fields (TTFields): advancements in clinical applications and mechanistic insights.
Li X, Liu K, Xing L, Rubinsky B. Li X, et al. Radiol Oncol. 2023 Sep 4;57(3):279-291. doi: 10.2478/raon-2023-0044. eCollection 2023 Sep 1. Radiol Oncol. 2023. PMID: 37665740 Free PMC article. Review.
Despite promising outcomes from clinical trials, TTFields have received FDA approval for the treatment of glioblastoma multiforme (GBM) and malignant pleural mesothelioma (MPM). Nevertheless, global acceptance of TTFields remains limited. To enhance its clinical app …
Despite promising outcomes from clinical trials, TTFields have received FDA approval for the treatment of glioblastoma multiforme (GB …
Dexamethasone and compliance affect TTFields efficacy to glioblastoma patients: a systematic review and meta-analysis.
Li S, Dong J, Wang X, Meng X, Jiang C, Cai J. Li S, et al. Chin Neurosurg J. 2022 Sep 3;8(1):24. doi: 10.1186/s41016-022-00294-0. Chin Neurosurg J. 2022. PMID: 36056409 Free PMC article. Review.

And the patients whose compliance of TTFields treatment 75% ( 18 h per day) have a significant lower overall survival risk than the patients whose compliance of TTFields treatment < 75% (HR = 0.57 [95% CI 0.46-0.70]; P < 0.00001).TTFields is a safe a

…
And the patients whose compliance of TTFields treatment 75% ( 18 h per day) have a significant lower overall survival risk than th …
Tumor-treating fields (TTFields)-based cocktail therapy: a novel blueprint for glioblastoma treatment.
Wang M, Zhang C, Wang X, Yu H, Zhang H, Xu J, Zhao J, Jiang X. Wang M, et al. Am J Cancer Res. 2021 Apr 15;11(4):1069-1086. eCollection 2021. Am J Cancer Res. 2021. PMID: 33948346 Free PMC article. Review.
Here, we introduced the current treatment regimen for glioblastoma, highlighting the unique advantages of TTFields in the treatment of glioblastoma. Then, we summarized current glioblastoma clinical trials that combine TTFields and other therapies. In addition, the …
Here, we introduced the current treatment regimen for glioblastoma, highlighting the unique advantages of TTFields in the treatment o …
Glioblastoma: Overview of Disease and Treatment.
Davis ME. Davis ME. Clin J Oncol Nurs. 2016 Oct 1;20(5 Suppl):S2-8. doi: 10.1188/16.CJON.S1.2-8. Clin J Oncol Nurs. 2016. PMID: 27668386 Free PMC article. Review.
Innovative treatments, such as tumor-treating fields (TTFields) and immunotherapy, give hope for enhanced survival. OBJECTIVES: This article reviews the background, risks, common complications, and treatment options for GBM. ...FINDINGS: Despite aggressive resection and co …
Innovative treatments, such as tumor-treating fields (TTFields) and immunotherapy, give hope for enhanced survival. OBJECTIVES: This …
428 results